

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Axcan Pharma US, Inc,		07/12/2011	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	Aptalis Pharma US, Inc.
Street Address:	100 Somerset Corporate Boulevard
Internal Address:	2nd Floor
City:	Bridgewater
State/Country:	NEW JERSEY
Postal Code:	08807
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 11

Property Type	Number	Word Mark
Serial Number:	77910147	
Registration Number:	1794089	SCANDI SHAKE
Registration Number:	2214800	SCANDICAL
Registration Number:	1764007	SCANDIPHARM
Registration Number:	1765728	SCANDIPHARM
Registration Number:	2532206	SCANDISHAKE
Registration Number:	1854418	ULTRASE
Serial Number:	77898302	ULTRESA
Serial Number:	77914922	ULTRESA
Serial Number:	77769231	ULTURA
Serial Number:	77771309	ULTYME

CORRESPONDENCE DATA

Fax Number: (703)816-4100

900208729

**TRADEMARK
 REEL: 004672 FRAME: 0163**

OP \$290.00 77910147

Phone: 703-816-4041
Email: fpp@nixonvan.com, cgp@nixonvan.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: Frank P. Presta, Nixon & Vanderhye PC
Address Line 1: 901 North Glebe Road
Address Line 2: 11th Floor
Address Line 4: Arlington, VIRGINIA 22203

ATTORNEY DOCKET NUMBER:	FPP-551-271
NAME OF SUBMITTER:	Frank P. Presta
Signature:	/fpp/
Date:	12/05/2011

Total Attachments: 3
source=Aptalis Pharma US, Inc#page1.tif
source=Aptalis Pharma US, Inc#page2.tif
source=Aptalis Pharma US, Inc#page3.tif

Delaware

PAGE 1

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "AXCAN PHARMA US, INC.", CHANGING ITS NAME FROM "AXCAN PHARMA US, INC." TO "APTALIS PHARMA US, INC.", FILED IN THIS OFFICE ON THE TWELFTH DAY OF JULY, A.D. 2011, AT 5:57 O'CLOCK P.M.


A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

2269607 8100

110814722

You may verify this certificate online
at corp.delaware.gov/authver.shtml




Jeffrey W. Bullock, Secretary of State
AUTHENTICATION: 8898775

DATE: 07-13-11

TRADEMARK
REEL: 004672 FRAME: 0165

CERTIFICATE OF AMENDMENT
TO CERTIFICATE OF INCORPORATION
OF
AXCAN PHARMA US, INC.

Axcán Pharma US, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:

FIRST: That at a meeting of the Board of Directors of Axcán Pharma US, Inc., resolutions were duly adopted setting forth a proposed amendment to the Certificate of Incorporation of said corporation, declaring said amendment to be advisable and calling a meeting of the stockholders of said corporation for consideration thereof. The resolution setting forth the proposed amendment is as follows:

"RESOLVED, That the Certificate of Incorporation of this corporation be amended by changing the Article First thereof so that, as amended said Article shall be and read as follows:

"FIRST: The name of the corporation is Aptalis Pharma US, Inc."


SECOND: That thereafter, pursuant to resolution of its Board of Directors, an annual meeting of the stockholders of said corporation was duly called and held, upon notice in accordance with Section 222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as required by statute were voted in favor of the amendment.

THIRD: That said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

FOURTH: That this Certificate of Amendment of the Certificate of Incorporation shall be effective upon filing with the Secretary of State.

IN WITNESS WHEREOF, said Axcan Pharma US, Inc. has caused this certificate to be signed by Theresa Stevens, its Senior VP, Chief Corporate Development Officer & Secretary this 28th day of June, 2011.

Axcan Pharma US, Inc.

By: 
Theresa Stevens, Senior VP, Chief
Corporate Development Officer and
Secretary